Pharma, Pharmaceutics and Biotechnology Conference

This consists of complex and multifaceted transformation of science findings to new therapeutics.

The session will focus on the stages involved in drug discovery but will concentrate on the more critical steps identification of the potential candidates, optimization of properties, and advancement toward clinical development. The discovery process usually begins with the identification of targets where the researchers identify biological molecules involved in disease pathways.

This session will focus on why one has to understand the mechanism of disease and role of genomics and proteomics in unearthing potential viable targets for intervention. It is important for precise identification of specific targets which are crucial in developing effective therapies capable of responding to the still-unmet medical needs.

Once a target is identified, lead discovery follows. This is essentially the screening of libraries of compounds to identify those that interact with the target and possess desired biological activity. Techniques in high-throughput screening have evolved this stage to the point where it is possible, within hours or days, to screen thousands of compounds for their potential effectiveness.

The course will discuss the various methods of screening and how the process itself has been improved through technology in order to produce viable drugs. Medicinal chemistry post the lead compounds by optimizing the pharmacological properties.

The principles of SAR analysis shall be talked about in this session. SAR analysis forms the bedrock guide that precedes the modification of chemical structures to enhance potency, selectivity, and safety.

Synthesis and testing in iterative steps are very important in refining candidates for lead selection before moving on to preclinical testing. In the area of preclinical testing, proper safety and efficacy could be examined through very detailed studies in vitro, or test tube studies, and even further studies in vivo, or animal studies.

This stage would be crucial for the assessment of the pharmacokinetics and toxicology of drug candidates before giving relevant data for regulatory submissions. Participants will gain insight into the regulatory landscape and why GLP is vital to maintaining the credibility of preclinical data.

Translating into clinical trials is quite a big leap as the drug discovery process progresses. The present session will be a special brief through the phases of clinical trials, and it will be shown that designing robust studies for the evaluation of new drugs into human populations is also very important in terms of their safety and efficacy.

They shall also be exposed to the current challenges and trends in drug discovery, including artificial intelligence and machine learning's effects in the design and development of drugs, revolutionizing pharmaceutical research by an effectiveness boost for the identification of candidates as well as predictive modeling.

In this session, a general overview of drug discovery has been made while keeping an emphasis on the extremely important role it plays in getting new therapeutics to the marketplace.

All participants will leave with an enormously deep understanding of the complexity of drug development and how these new approaches are transforming the pharmaceutical industry.